Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIKUNJ N SHAH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1134109861
CMS profile
6048
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,025.17

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $686.05 2
Food and Beverage $339.12 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $876.05 3
Allergan Inc. $114.09 1
Alnylam Pharmaceuticals Inc. $35.03 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIKUNJ N SHAH

NPI 1134109861 · CMS profile ID 6048

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIKUNJ N SHAH, NPI 1134109861, CMS profile ID 6048. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NIKUNJ N SHAH, NPI 1134109861, CMS profile ID 6048. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NIKUNJ N SHAH, NPI 1134109861, CMS profile ID 6048, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,025.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alnylam Pharmaceuticals Inc. $35.0311/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701568981 CMS
Celgene Corporation $508.6009/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672926803 CMS
Celgene Corporation $177.4509/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672969019 CMS
Celgene Corporation $190.0009/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672969105 CMS
Allergan Inc. $114.0904/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671120865 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,025.17 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $14,196.00 2
PY2023 Principal investigator $4,123.60 1
PY2022 Recipient $1,050.00 1
PY2022 Principal investigator $50,173.36 7
PY2021 Principal investigator $109,994.91 66
PY2020 Principal investigator $59,082.50 29
PY2019 Recipient $1,564.98 10
PY2019 Principal investigator $89,350.75 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $53,252.25 12/17/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 670012165
Principal investigator 1 Allergan Inc. $1,121.00 12/16/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012161
Principal investigator 1 Allergan Inc. $300.00 12/04/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012139
Principal investigator 1 Allergan Inc. $400.00 12/04/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012145
Principal investigator 1 Allergan Inc. $300.00 12/04/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012149
Principal investigator 1 Allergan Inc. $975.00 12/04/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012153
Principal investigator 1 Allergan Inc. $150.00 12/04/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012155
Principal investigator 1 Allergan Inc. $975.00 12/04/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012157
Principal investigator 1 Allergan Inc. $1,121.00 11/15/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012137
Recipient Gilead Sciences, Inc. $77.86 11/08/2019 Covered Recipient Physician STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis No dispute reported 06/30/2026 676479347
Principal investigator 1 Allergan Inc. $665.00 10/22/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012133
Principal investigator 1 Allergan Inc. $2,242.00 10/16/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis NASH No dispute reported 06/30/2026 670012127
Principal investigator 1 Allergan Inc. $665.00 09/24/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012121
Principal investigator 1 Allergan Inc. $783.75 09/19/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012115
Principal investigator 1 Allergan Inc. $7,210.50 08/13/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012111
Principal investigator 1 Allergan Inc. $2,242.00 08/06/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670012107
Principal investigator 1 Allergan Inc. $1,121.00 05/16/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670012093
Recipient Gilead Sciences, Inc. $30.47 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479299
Recipient Gilead Sciences, Inc. $49.96 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479307
Recipient Gilead Sciences, Inc. $49.99 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479313
Recipient Gilead Sciences, Inc. $49.99 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479317
Recipient Gilead Sciences, Inc. $55.99 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479323
Recipient Gilead Sciences, Inc. $124.99 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479327
Recipient Gilead Sciences, Inc. $127.18 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479331
Recipient Gilead Sciences, Inc. $459.96 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479337
Recipient Gilead Sciences, Inc. $538.59 04/26/2019 Covered Recipient Physician A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 676479341
Principal investigator 1 Allergan Inc. $665.00 04/23/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012089
Principal investigator 1 Gilead Sciences, Inc. $3,538.00 04/17/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487365
Principal investigator 1 Gilead Sciences, Inc. $777.00 03/20/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487359
Principal investigator 1 Allergan Inc. $1,092.50 02/26/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012081
Principal investigator 1 Allergan Inc. $1,121.00 02/12/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670012075
Principal investigator 1 Allergan Inc. $2,968.75 01/29/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 670012071
Principal investigator 1 Gilead Sciences, Inc. $1,327.00 01/28/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487353
Principal investigator 1 Gilead Sciences, Inc. $975.00 01/23/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
STELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 676487349
Principal investigator 1 Allergan Inc. $3,363.00 01/15/2019 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
OPEN-LABEL ROLLOVER STUDY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS NASH No dispute reported 06/30/2026 670012067